AZN Klygefa Wins CHMP Nod for Generalized Myasthenia Gravis

The European Medicines Agency’s CHMP has recommended approval of Alexion’s Klygefa (gefurulimab) for adults with generalized myasthenia gravis (gMG) who test positive for acetylcholine-receptor (AChR) antibodies. The positive opinion, adopted September 17, clears the way for a European Commission decision expected within roughly two months. AstraZeneca’s ADR (AZN) closed at $166.58 on Friday, little changed on what is an EU-only milestone.

Myasthenia gravis is an autoimmune disease in which antibodies attack the connection between nerves and muscles, causing weakness and fatigue that can impair breathing and swallowing in severe cases. Roughly 85% of patients are AChR-antibody positive, so the label covers most of the disease.

Klygefa is a dual-binding nanobody, a small engineered antibody fragment that blocks complement protein C5. In gMG, the complement cascade attacks the neuromuscular junction, so switching off C5 helps preserve muscle strength. Unlike Alexion’s two existing intravenous C5 drugs, Soliris (given every two weeks) and Ultomiris (every eight weeks), Klygefa is a once-weekly self-administered injection under the skin. If the Commission approves it, Klygefa would be the first and only dual-binding nanobody C5 inhibitor for gMG in the EU.

The recommendation rests on the PREVAIL Phase 3 trial (NCT05556096), which met its primary endpoint of lowering the Myasthenia Gravis Activities of Daily Living (MG-ADL) score at week 26 and hit every secondary endpoint. Improvement appeared as early as week one and held through week 26. The results were published in JAMA Neurology. Like every C5 inhibitor, Klygefa carries a boxed warning for serious meningococcal infections, which means patients need meningococcal vaccination before starting treatment.

The strategic story is franchise defense. Alexion already leads gMG with Soliris and Ultomiris, but rivals argenx’s Vyvgart and UCB’s Rystiggo, both FcRn inhibitors, already offer subcutaneous dosing, and a weekly at-home C5 option is how Alexion keeps complement patients from drifting to a rival mechanism. Self-administered therapy also spares patients the travel and time of infusion-center visits. Alexion has spent more than three decades building its complement franchise, and gMG is one of its largest indications. Klygefa holds US Orphan Drug Designation for myasthenia gravis, granted in August 2023.

The caveat is geographic. This is a European milestone, and no US filing has been announced, so it does not change AstraZeneca’s near-term story. In the US, Vyvgart and Rystiggo are already approved for gMG, and Regeneron’s cemdisiran, another C5 inhibitor, has a November PDUFA date. The next catalysts are the European Commission’s final decision, then any US BLA filing.

What to watch next: the Commission decision, which typically lands about two months after a positive CHMP opinion. For the competitive setup in gMG, read the gMG PDUFA primer on Regeneron’s cemdisiran.

Source: AstraZeneca Klygefa CHMP recommendation press release · PREVAIL trial on ClinicalTrials.gov (NCT05556096)

What It Means for the Trade

Strip out the noise first: this is not a reason to buy AstraZeneca. AZN is a diversified mega-cap, and a European gMG launch — even a franchise-defending one — is a rounding error against a revenue base of that size. What the CHMP opinion actually does is buy time for the complement franchise in Europe. Vyvgart and Rystiggo already offer subcutaneous dosing there, and once a patient switches off a C5 inhibitor onto an FcRn drug, they rarely come back. A once-weekly, at-home C5 option gives the Alexion salesforce a concrete reason to keep complement patients on complement therapy.

The catalyst path is short and legible: a European Commission decision in roughly two months, which typically follows a positive CHMP opinion without drama. The open question is the US — no filing has been announced, and cemdisiran’s November PDUFA could hand Regeneron the first subcutaneous C5 stateside before Klygefa even gets a US docket date.

Mechanism and Market Context

The product logic is a convenience play on a proven mechanism. C5 blockade works in gMG — Soliris and Ultomiris proved it — but both are intravenous, and infusion logistics are exactly why patients drift toward FcRn rivals. Klygefa’s dual-binding nanobody is small enough for once-weekly self-injection while hitting the same C5 target, making it the first C5 option that matches the administration profile patients now expect. The AChR-antibody-positive label covers roughly 85% of gMG patients, so the addressable population is nearly the whole disease. The boxed meningococcal warning is class-wide rather than a differentiator — every C5 inhibitor carries it, and pre-treatment vaccination is a known cost of complement blockade, not a strike against this specific drug.

Risks and What Could Go Wrong

1. Commission timing slips past the two-month window — unlikely, but the EU decision is the only near-term catalyst, and a delay leaves the story without a fresh driver.
2. No announced US filing means cemdisiran could lock up the subcutaneous C5 position in the larger US market first, eroding Klygefa’s differentiation before it exists there.
3. Europe is rough terrain for premium launch pricing — reference pricing across member states compresses the economics of what is fundamentally a franchise-defense product.